Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
195 participants
INTERVENTIONAL
2023-02-05
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SightGlass Vision Test Arm 1
Single vision, impact-resistant spectacle lenses
Novel spectacle lens design
Use of lenses may reduce the rate of progression of juvenile myopia
Test Arm 2
Single vision, impact-resistant spectacle lenses
Spectacle lenses
Use of lenses may reduce the rate of progression of juvenile myopia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Novel spectacle lens design
Use of lenses may reduce the rate of progression of juvenile myopia
Spectacle lenses
Use of lenses may reduce the rate of progression of juvenile myopia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. SER error between -0.75D and -5.00D
3. Willingness to wear study spectacles and participate in the trial for 12 months without contact lens wear
Exclusion Criteria
2. Astigmatism worse than -1.50 DC (by manifest refraction) in either eye
3. Anisometropia (SER manifest refraction) greater than 1.00 D
6 Years
13 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SightGlass Vision, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aier Eye Hospital
Changsha, , China
West China Hospital
Chengdu, , China
Zhongshan Ophthalmic Center
Guangzhou, , China
Fudan University EENT
Shanghai, , China
Tianjin Eye Hospital
Tianjin, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CPRO-2201-001
Identifier Type: -
Identifier Source: org_study_id